These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 9677006)

  • 1. Improvements and new potentials in pharmacological therapy of diabetes mellitus in children and adolescents.
    Kiess W; Kapellen T; Siebler T; Dost A; Deutscher J; Nietzschmann U
    Horm Res; 1998; 50 Suppl 1():87-90. PubMed ID: 9677006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insulins and other possible therapeutic approaches.
    Johannesen J; Petersen KF; Berger M; Binder C
    Diabetologia; 1997 Oct; 40 Suppl 3():B89-93. PubMed ID: 9345654
    [No Abstract]   [Full Text] [Related]  

  • 3. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone.
    Edelman SV; Weyer C
    Diabetes Technol Ther; 2002; 4(2):175-89. PubMed ID: 12079621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin analogues in children and teens with type 1 diabetes: advantages and caveats.
    Rachmiel M; Perlman K; Daneman D
    Pediatr Clin North Am; 2005 Dec; 52(6):1651-75. PubMed ID: 16301087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
    Baron AD; Kim D; Weyer C
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ; Jobe LJ; Martin R
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel pharmacologic agents for type 2 diabetes.
    Uwaifo GI; Ratner RE
    Endocrinol Metab Clin North Am; 2005 Mar; 34(1):155-97. PubMed ID: 15752927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramlintide in the treatment of diabetes.
    Edelman SV; Darsow T; Frias JP
    Int J Clin Pract; 2006 Dec; 60(12):1647-53. PubMed ID: 17109671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is pramlintide an adjunct to insulin therapy?
    Charles MA
    Diabetes Technol Ther; 2002; 4(2):190-2. PubMed ID: 12079622
    [No Abstract]   [Full Text] [Related]  

  • 10. [Role of amylin in glucose homeostasis and its perspective use in diabetes management].
    Otto-Buczkowska E; Mazur-Dworzecka U; Dworzecki T
    Przegl Lek; 2008; 65(3):135-9. PubMed ID: 18624122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of Lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with type 1 diabetes.
    Griffen SC; Oostema K; Stanhope KL; Graham J; Styne DM; Glaser N; Cummings DE; Connors MH; Havel PJ
    J Clin Endocrinol Metab; 2006 Feb; 91(2):485-91. PubMed ID: 16317063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin increases serum leptin concentrations in children and adolescents with newly diagnosed type I diabetes mellitus with and without ketoacidosis.
    Flück CE; Kuhlmann BV; Mullis PE
    Diabetologia; 1999 Sep; 42(9):1067-70. PubMed ID: 10447517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretins, amylin and other gut-brain axis hormones in children with coeliac disease.
    Papastamataki M; Papassotiriou I; Bartzeliotou A; Vazeou A; Roma E; Chrousos GP; Kanaka-Gantenbein C
    Eur J Clin Invest; 2014 Jan; 44(1):74-82. PubMed ID: 24151959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatments of diabetes: the beta-amylin agonists.
    Lebovitz HE
    Ann Endocrinol (Paris); 2008 Apr; 69(2):147-50. PubMed ID: 18423421
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of Amylin in Type 1 and Type 2 Diabetes.
    Hieronymus L; Griffin S
    Diabetes Educ; 2015 Dec; 41(1 Suppl):47S-56S. PubMed ID: 26424675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
    Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: Differences in the dawn phenomenon between insulin regimens.
    Yagasaki H; Kobayashi K; Saitou T; Nagamine K; Mitsui Y; Mochizuki M; Kobayashi K; Cho H; Ohyama K; Amemiya S; Nakazawa S
    Exp Clin Endocrinol Diabetes; 2010 Mar; 118(3):195-9. PubMed ID: 19834874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
    Singh-Franco D; Robles G; Gazze D
    Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretins and amylin in pediatric diabetes: new tools for management of diabetes in youth.
    Wood JR; Silverstein J
    Curr Opin Pediatr; 2013 Aug; 25(4):502-8. PubMed ID: 23782574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of insulin-like growth factor-I in the control of glucose homeostasis.
    Clemmons DR
    Curr Opin Pharmacol; 2006 Dec; 6(6):620-5. PubMed ID: 17030015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.